These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 15149782)

  • 1. Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine.
    Borja-Cabrera GP; Cruz Mendes A; Paraguai de Souza E; Hashimoto Okada LY; de A Trivellato FA; Kawasaki JK; Costa AC; Reis AB; Genaro O; Batista LM; Palatnik M; Palatnik-de-Sousa CB
    Vaccine; 2004 Jun; 22(17-18):2234-43. PubMed ID: 15149782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (São Gonçalo do Amarante, RN).
    Borja-Cabrera GP; Correia Pontes NN; da Silva VO; Paraguai de Souza E; Santos WR; Gomes EM; Luz KG; Palatnik M; Palatnik de Sousa CB
    Vaccine; 2002 Sep; 20(27-28):3277-84. PubMed ID: 12213397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis.
    Oliveira-Freitas E; Casas CP; Borja-Cabrera GP; Santos FN; Nico D; Souza LO; Tinoco LW; da Silva BP; Palatnik M; Parente JP; Palatnik-de-Sousa CB
    Vaccine; 2006 May; 24(18):3909-20. PubMed ID: 16556475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leishmune vaccine blocks the transmission of canine visceral leishmaniasis: absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs.
    Nogueira FS; Moreira MA; Borja-Cabrera GP; Santos FN; Menz I; Parra LE; Xu Z; Chu HJ; Palatnik-de-Sousa CB; Luvizotto MC
    Vaccine; 2005 Sep; 23(40):4805-10. PubMed ID: 16011864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The FML-vaccine (Leishmune) against canine visceral leishmaniasis: a transmission blocking vaccine.
    Saraiva EM; de Figueiredo Barbosa A; Santos FN; Borja-Cabrera GP; Nico D; Souza LO; de Oliveira Mendes-Aguiar C; de Souza EP; Fampa P; Parra LE; Menz I; Dias JG; de Oliveira SM; Palatnik-de-Sousa CB
    Vaccine; 2006 Mar; 24(13):2423-31. PubMed ID: 16386824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune vaccine.
    Santos FN; Borja-Cabrera GP; Miyashiro LM; Grechi J; Reis AB; Moreira MA; Martins Filho OA; Luvizotto MC; Menz I; Pessôa LM; Gonçalves PR; Palatnik M; Palatnik-de-Sousa CB
    Vaccine; 2007 Aug; 25(33):6176-90. PubMed ID: 17630055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IgG1/IgG2 antibody dichotomy in sera of vaccinated or naturally infected dogs with visceral leishmaniosis.
    de Oliveira Mendes C; Paraguai de Souza E; Borja-Cabrera GP; Maria Melo Batista L; Aparecida dos Santos M; Ellner Parra L; Menz I; Palatnik M; Palatnik de Sousa CB
    Vaccine; 2003 Jun; 21(19-20):2589-97. PubMed ID: 12744895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy against murine experimental visceral leishmaniasis with the FML-vaccine.
    Santos WR; Aguiar IA; Paraguai de Souza E; de Lima VM; Palatnik M; Palatnik-de-Sousa CB
    Vaccine; 2003 Dec; 21(32):4668-76. PubMed ID: 14585674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (São Gonçalo do Amaranto, RN).
    da Silva VO; Borja-Cabrera GP; Correia Pontes NN; de Souza EP; Luz KG; Palatnik M; Palatnik de Sousa CB
    Vaccine; 2000 Dec; 19(9-10):1082-92. PubMed ID: 11137242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity assay of the Leishmune vaccine against canine visceral leishmaniasis in Brazil.
    Borja-Cabrera GP; Santos FN; Bauer FS; Parra LE; Menz I; Morgado AA; Soares IS; Batista LM; Palatnik-de-Sousa CB
    Vaccine; 2008 Sep; 26(39):4991-7. PubMed ID: 18675868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
    Lemesre JL; Holzmuller P; Gonçalves RB; Bourdoiseau G; Hugnet C; Cavaleyra M; Papierok G
    Vaccine; 2007 May; 25(21):4223-34. PubMed ID: 17395339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis.
    Aguilar-Be I; da Silva Zardo R; Paraguai de Souza E; Borja-Cabrera GP; Rosado-Vallado M; Mut-Martin M; García-Miss Mdel R; Palatnik de Sousa CB; Dumonteil E
    Infect Immun; 2005 Feb; 73(2):812-9. PubMed ID: 15664920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis.
    Santos WR; de Lima VM; de Souza EP; Bernardo RR; Palatnik M; Palatnik de Sousa CB
    Vaccine; 2002 Nov; 21(1-2):30-43. PubMed ID: 12443660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokine Profile of Leishmania Infantum Fucose-Mannose Ligand in Vaccinated Dogs in the Northwest of Iran.
    Mohammadi-Ghalehbin B; Hatam G; Sarkari B; Mohebali M; Zarei Z; Bohlooli S
    Iran J Immunol; 2017 Dec; 14(4):293-305. PubMed ID: 29276182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haemolytic activities of plant saponins and adjuvants. Effect of Periandra mediterranea saponin on the humoral response to the FML antigen of Leishmania donovani.
    Santos WR; Bernardo RR; Peçanha LM; Palatnik M; Parente JP; Palatnik de Sousa CB
    Vaccine; 1997 Jun; 15(9):1024-9. PubMed ID: 9261952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy with the saponin enriched-Leishmune vaccine versus immunochemotherapy in dogs with natural canine visceral leishmaniasis.
    Borja-Cabrera GP; Santos FN; Santos FB; Trivellato FA; Kawasaki JK; Costa AC; Castro T; Nogueira FS; Moreira MA; Luvizotto MC; Palatnik M; Palatnik-de-Sousa CB
    Vaccine; 2010 Jan; 28(3):597-603. PubMed ID: 19800443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody responses induced by Leish-Tec®, an A2-based vaccine for visceral leishmaniasis, in a heterogeneous canine population.
    Testasicca MC; dos Santos MS; Machado LM; Serufo AV; Doro D; Avelar D; Tibúrcio AM; Abrantes Cde F; Machado-Coelho GL; Grimaldi G; Gazzinelli RT; Fernandes AP
    Vet Parasitol; 2014 Aug; 204(3-4):169-76. PubMed ID: 24863572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of a recombinant cysteine proteinase from Leishmania (Leishmania) infantum chagasi for the Immunotherapy of canine visceral Leishmaniasis.
    Ferreira JH; Silva Ldos S; Longo-Maugéri IM; Katz S; Barbiéri CL
    PLoS Negl Trop Dis; 2014 Mar; 8(3):e2729. PubMed ID: 24625516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, controlled, double-blinded field trial to assess Leishmania vaccine effectiveness as immunotherapy for canine leishmaniosis.
    Toepp A; Larson M; Wilson G; Grinnage-Pulley T; Bennett C; Leal-Lima A; Anderson B; Parrish M; Anderson M; Fowler H; Hinman J; Kontowicz E; Jefferies J; Beeman M; Buch J; Saucier J; Tyrrell P; Gharpure R; Cotter C; Petersen C
    Vaccine; 2018 Oct; 36(43):6433-6441. PubMed ID: 30219369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diminished CD4+/CD25+ T cell and increased IFN-gamma levels occur in dogs vaccinated with Leishmune in an endemic area for visceral leishmaniasis.
    de Lima VM; Ikeda FA; Rossi CN; Feitosa MM; Vasconcelos RO; Nunes CM; Goto H
    Vet Immunol Immunopathol; 2010 Jun; 135(3-4):296-302. PubMed ID: 20132994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.